226 related articles for article (PubMed ID: 20689431)
21. Lenalidomide for mantle cell lymphoma.
Skarbnik AP; Goy AH
Expert Rev Hematol; 2015 Jun; 8(3):257-64. PubMed ID: 25952533
[TBL] [Abstract][Full Text] [Related]
22. Role of lenalidomide in the treatment of multiple myeloma and myelodysplastic syndrome.
Maier SK; Hammond JM
Ann Pharmacother; 2006 Feb; 40(2):286-9. PubMed ID: 16403850
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of action of lenalidomide in hematological malignancies.
Kotla V; Goel S; Nischal S; Heuck C; Vivek K; Das B; Verma A
J Hematol Oncol; 2009 Aug; 2():36. PubMed ID: 19674465
[TBL] [Abstract][Full Text] [Related]
24. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Ladizinski B; Shannon EJ; Sanchez MR; Levis WR
J Drugs Dermatol; 2010 Jul; 9(7):814-26. PubMed ID: 20677538
[TBL] [Abstract][Full Text] [Related]
25. [Lenalidomide in hematological malignancies---review].
Jin X; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
[TBL] [Abstract][Full Text] [Related]
26. [Action mechanism of lenalidomide in hematological malignancies - review].
Liu LR; Qian SX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):1039-41. PubMed ID: 22931680
[TBL] [Abstract][Full Text] [Related]
27. Current status of thalidomide in the treatment of cancer.
Rajkumar SV
Oncology (Williston Park); 2001 Jul; 15(7):867-74; discussion 877-9. PubMed ID: 11499688
[TBL] [Abstract][Full Text] [Related]
28. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.
Rajkumar SV; Witzig TE
Cancer Treat Rev; 2000 Oct; 26(5):351-62. PubMed ID: 11006136
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
Xiong B; Liu X; Zou P; Fan L; Chen W; Li W; Liu L
Leuk Res; 2010 Jul; 34(7):e169-72. PubMed ID: 20122730
[No Abstract] [Full Text] [Related]
30. IMiDs New and Old.
Yamshon S; Ruan J
Curr Hematol Malig Rep; 2019 Oct; 14(5):414-425. PubMed ID: 31302872
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic renaissance of thalidomide in the treatment of haematological malignancies.
Ribatti D; Vacca A
Leukemia; 2005 Sep; 19(9):1525-31. PubMed ID: 15973447
[TBL] [Abstract][Full Text] [Related]
32. [Immunomodulatory drugs (IMiDs)].
Oshima K; Ichinohe T
Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo.
Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC
Leukemia; 2003 Jan; 17(1):41-4. PubMed ID: 12529658
[TBL] [Abstract][Full Text] [Related]
34. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.
Schafer PH
Expert Opin Pharmacother; 2012 Jul; 13(10):1541-2. PubMed ID: 22646699
[No Abstract] [Full Text] [Related]
35. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
36. [An old drug as a carcinostatic. The new career of thalidomide].
Holzgrabe U
Pharm Unserer Zeit; 2007; 36(6):446-9. PubMed ID: 17957689
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological properties of thalidomide and its analogues.
De Sanctis JB; Mijares M; Suárez A; Compagnone R; Garmendia J; Moreno D; Salazar-Bookaman M
Recent Pat Inflamm Allergy Drug Discov; 2010 Jun; 4(2):144-8. PubMed ID: 20307255
[TBL] [Abstract][Full Text] [Related]
38. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
39. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
Melchert M; Kale V; List A
Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good?
Sekeres MA; List A
Curr Hematol Rep; 2005 May; 4(3):182-5. PubMed ID: 15865869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
